polyclonal ab against igf 1r Search Results


95
R&D Systems sheep polyclonal antibody against cd31 pecam 1
Sheep Polyclonal Antibody Against Cd31 Pecam 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/sheep polyclonal antibody against cd31 pecam 1/product/R&D Systems
Average 95 stars, based on 1 article reviews
sheep polyclonal antibody against cd31 pecam 1 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier

93
Bioss anti igf 1r
Anti Igf 1r, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti igf 1r/product/Bioss
Average 93 stars, based on 1 article reviews
anti igf 1r - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

90
Cell Signaling Technology Inc rabbit polyclonal antibodies against igf-1r
Rabbit Polyclonal Antibodies Against Igf 1r, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal antibodies against igf-1r/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
rabbit polyclonal antibodies against igf-1r - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
R&D Systems antibodies against kim-1
Antibodies Against Kim 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against kim-1/product/R&D Systems
Average 90 stars, based on 1 article reviews
antibodies against kim-1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
R&D Systems goat polyclonal anti human epcam trop 1
Goat Polyclonal Anti Human Epcam Trop 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/goat polyclonal anti human epcam trop 1/product/R&D Systems
Average 93 stars, based on 1 article reviews
goat polyclonal anti human epcam trop 1 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

93
Bioss rabbit polyclonal antibody against glp 1r
Rabbit Polyclonal Antibody Against Glp 1r, supplied by Bioss, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal antibody against glp 1r/product/Bioss
Average 93 stars, based on 1 article reviews
rabbit polyclonal antibody against glp 1r - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

94
R&D Systems anti mouse lyve 1
Anti Mouse Lyve 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti mouse lyve 1/product/R&D Systems
Average 94 stars, based on 1 article reviews
anti mouse lyve 1 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology primary antibody against igf-1r
Transfection efficiency of <t>IGF-1r</t> siRNA in vitro . (A) IGF-1r protein expression was analyzed by Western blotting after transfection with IGF-1r siRNA for 72 hours in TE-1 and Eca-109 cells. (B) The transfection efficiency of IGF-1r siRNA was observed by fluorescence microscopy after 72 hours in TE-1 and Eca-109 cells. β-actin was used as a loading control.
Primary Antibody Against Igf 1r, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibody against igf-1r/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
primary antibody against igf-1r - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

90
Santa Cruz Biotechnology antibodies against actin
(a and b) The effects of vorinostat on the viability (a) and anchorage-independent colony formation (b) of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. (a) Cell viability was determined by the MTT assay ( n = 3). (b) The soft agar colony formation assay was performed to evaluate the effect of 1 μM vorinostat on anchorage-independent colony formation. Data indicates the percentage of colony formation in vorinostat-treated cells compared with vehicle-treated control cells ( n = 3). (c) Immunoblots comparing the expression of cleaved caspase-3 (cl-Cas-3) between the indicated parental and VoR sublines. Cells were treated with vorinostat for 2 days. (d) The MTT assay evaluating the effect of romidepsin (Romi) on the viability of H1944 and H1944R cells. Cells were treated with indicated concentrations of romidepsin for 3 days ( n = 3). (e) The expression levels of total and phosphorylated <t>IGF-1R</t> in the indicated NSCLC cells were determined by Western blot analysis. Cells were treated with vorinostat for 2 days. (f) Anchorage-independent colony formation assay evaluating vorinostat resistance of the indicated cells with combined treatment with vorinostat (1 μM) and an IGF-1R mAb (1 μg/ml) ( n = 3). **: P < 0.01; ***: P < 0.001, analyzed by two-sided Student’s t -test. Vo: vorinostat; Con: control.
Antibodies Against Actin, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/antibodies against actin/product/Santa Cruz Biotechnology
Average 90 stars, based on 1 article reviews
antibodies against actin - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

94
R&D Systems anti human tim 1
(A) All three members of human TIM family interact with NUR77 as shown by coimmunoprecipitation assay. N=3 independent experiments (B) Top panel: Domain architecture of <t>TIM-1.</t> Middle Panel: Coimmunoprecipitation experiment demonstrating that only the entire extracellular domain (EED) and IgV domain (IgVD) of TIM-1 interact with NUR77 and not the mucin (MD) or the cytoplasmic domain (CD). Bottom panel: long exposure of the input blot showing the CD protein band. N=2 independent experiments. (C) The transactivation function of NUR77 is repressed by all three human TIM proteins in a dose dependent manner (Top panel). Full length TIM-1 protein is required for repression of NUR77 transcriptional activity (Bottom panel). Data from at least three independent experiments is presented. (D) Binding of NUR77 to its response elements (NBRE) is abrogated by the full length TIM proteins in an electrophoretic mobility shift assay using p32 labeled NBRE oligo. Competition with unlabelled probe (cold competition) reveals the specificity of NUR77 binding. A representative autoradiograph is shown (left) and the relative amount of NUR77 protein binding to NBRE probe was quantified from three independent experiments (right). ***, P<0.001, **, P<0.01, *,P<0.05.
Anti Human Tim 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human tim 1/product/R&D Systems
Average 94 stars, based on 1 article reviews
anti human tim 1 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

90
R&D Systems primary antibodies against vegfr-1
P5 retinal whole-mount in situ hybridization of VEGF-A, <t>VEGFR-1,</t> and VEGFR-2 mRNA’s. (a) VEGF-A mRNA (pink) is detected anterior to the growing vessel front as outlined by (b) FITC-dextran perfusion of vessels (yellow green). Posterior to the vessel front, VEGF-A expression is suppressed (light yellow). (c) VEGFR-1 mRNA (pink) is detected in the central retina but is not seen at the anterior edge of vessels as outlined by (d) FITC-dextran perfusion of vessels (yellow). (e) VEGFR-2 mRNA (pink) is detected in the entire retina and does not correspond to the vessels (f) outlined in yellow.
Primary Antibodies Against Vegfr 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/primary antibodies against vegfr-1/product/R&D Systems
Average 90 stars, based on 1 article reviews
primary antibodies against vegfr-1 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

94
R&D Systems monoclonal antibody against tgf β 1
P5 retinal whole-mount in situ hybridization of VEGF-A, <t>VEGFR-1,</t> and VEGFR-2 mRNA’s. (a) VEGF-A mRNA (pink) is detected anterior to the growing vessel front as outlined by (b) FITC-dextran perfusion of vessels (yellow green). Posterior to the vessel front, VEGF-A expression is suppressed (light yellow). (c) VEGFR-1 mRNA (pink) is detected in the central retina but is not seen at the anterior edge of vessels as outlined by (d) FITC-dextran perfusion of vessels (yellow). (e) VEGFR-2 mRNA (pink) is detected in the entire retina and does not correspond to the vessels (f) outlined in yellow.
Monoclonal Antibody Against Tgf β 1, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/monoclonal antibody against tgf β 1/product/R&D Systems
Average 94 stars, based on 1 article reviews
monoclonal antibody against tgf β 1 - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

Image Search Results


Transfection efficiency of IGF-1r siRNA in vitro . (A) IGF-1r protein expression was analyzed by Western blotting after transfection with IGF-1r siRNA for 72 hours in TE-1 and Eca-109 cells. (B) The transfection efficiency of IGF-1r siRNA was observed by fluorescence microscopy after 72 hours in TE-1 and Eca-109 cells. β-actin was used as a loading control.

Journal: World Journal of Surgical Oncology

Article Title: Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo

doi: 10.1186/1477-7819-12-325

Figure Lengend Snippet: Transfection efficiency of IGF-1r siRNA in vitro . (A) IGF-1r protein expression was analyzed by Western blotting after transfection with IGF-1r siRNA for 72 hours in TE-1 and Eca-109 cells. (B) The transfection efficiency of IGF-1r siRNA was observed by fluorescence microscopy after 72 hours in TE-1 and Eca-109 cells. β-actin was used as a loading control.

Article Snippet: After blocking, the membrane was incubated overnight at 4°C with a primary antibody against IGF-1r (1:1,000; Santa Cruz Biotechnology, Santa Cruz, California, United States), followed by horseradish peroxidase-conjugated secondary antibody.

Techniques: Transfection, In Vitro, Expressing, Western Blot, Fluorescence, Microscopy, Control

Effect of combination therapy on the growth of esophageal squamous cell carcinoma cell lines in vitro . (A , B) Cell proliferation of Eca-109 cells was influenced after γ-irradiation at 4 Gy/min (IR) in the presence or absence of IGF-1r siRNA. (C , D) Cell proliferation of TE-1 cells was influenced after γ-irradiation at 4 Gy/min (IR) in the presence or absence of IGF-1r siRNA. Bars indicate the standard deviation of the mean. Each experiment was performed in triplicate. (The criterion for statistical significance was *, ** and *** as p < 0.05, 0.01 and 0.001, respectively).

Journal: World Journal of Surgical Oncology

Article Title: Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo

doi: 10.1186/1477-7819-12-325

Figure Lengend Snippet: Effect of combination therapy on the growth of esophageal squamous cell carcinoma cell lines in vitro . (A , B) Cell proliferation of Eca-109 cells was influenced after γ-irradiation at 4 Gy/min (IR) in the presence or absence of IGF-1r siRNA. (C , D) Cell proliferation of TE-1 cells was influenced after γ-irradiation at 4 Gy/min (IR) in the presence or absence of IGF-1r siRNA. Bars indicate the standard deviation of the mean. Each experiment was performed in triplicate. (The criterion for statistical significance was *, ** and *** as p < 0.05, 0.01 and 0.001, respectively).

Article Snippet: After blocking, the membrane was incubated overnight at 4°C with a primary antibody against IGF-1r (1:1,000; Santa Cruz Biotechnology, Santa Cruz, California, United States), followed by horseradish peroxidase-conjugated secondary antibody.

Techniques: In Vitro, Irradiation, Standard Deviation

Effect of combination therapy on apoptosis in TE-1 and Eca-109 cells. (A) Eca-109 and (B) TE-1 cells were γ-irradiated at 4 Gy/min in the presence or absence of IGF-1r siRNA and then evaluated by flow cytometry. Bars indicate the standard deviation of the mean. Each experiment was performed in triplicate.

Journal: World Journal of Surgical Oncology

Article Title: Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo

doi: 10.1186/1477-7819-12-325

Figure Lengend Snippet: Effect of combination therapy on apoptosis in TE-1 and Eca-109 cells. (A) Eca-109 and (B) TE-1 cells were γ-irradiated at 4 Gy/min in the presence or absence of IGF-1r siRNA and then evaluated by flow cytometry. Bars indicate the standard deviation of the mean. Each experiment was performed in triplicate.

Article Snippet: After blocking, the membrane was incubated overnight at 4°C with a primary antibody against IGF-1r (1:1,000; Santa Cruz Biotechnology, Santa Cruz, California, United States), followed by horseradish peroxidase-conjugated secondary antibody.

Techniques: Irradiation, Flow Cytometry, Standard Deviation

Therapeutic effect of irradiation combined with IGF-1r siRNA in vivo . The survival fraction after treatment is shown for (A) Eca-109 and (B) TE-1 cells, respectively. Irradiation alone enhanced tumor growth inhibition and led to shorter survival times than the combination treatment. The tumor volume was calculated at the indicated times in the (C) Eca-109 and (D) TE-1 cell groups, respectively. The statistical significance of the tumor volume changes was calculated using Student’s t-test.

Journal: World Journal of Surgical Oncology

Article Title: Silencing of insulin-like growth factor-1 receptor enhances the radiation sensitivity of human esophageal squamous cell carcinoma in vitro and in vivo

doi: 10.1186/1477-7819-12-325

Figure Lengend Snippet: Therapeutic effect of irradiation combined with IGF-1r siRNA in vivo . The survival fraction after treatment is shown for (A) Eca-109 and (B) TE-1 cells, respectively. Irradiation alone enhanced tumor growth inhibition and led to shorter survival times than the combination treatment. The tumor volume was calculated at the indicated times in the (C) Eca-109 and (D) TE-1 cell groups, respectively. The statistical significance of the tumor volume changes was calculated using Student’s t-test.

Article Snippet: After blocking, the membrane was incubated overnight at 4°C with a primary antibody against IGF-1r (1:1,000; Santa Cruz Biotechnology, Santa Cruz, California, United States), followed by horseradish peroxidase-conjugated secondary antibody.

Techniques: Irradiation, In Vivo, Inhibition

(a and b) The effects of vorinostat on the viability (a) and anchorage-independent colony formation (b) of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. (a) Cell viability was determined by the MTT assay ( n = 3). (b) The soft agar colony formation assay was performed to evaluate the effect of 1 μM vorinostat on anchorage-independent colony formation. Data indicates the percentage of colony formation in vorinostat-treated cells compared with vehicle-treated control cells ( n = 3). (c) Immunoblots comparing the expression of cleaved caspase-3 (cl-Cas-3) between the indicated parental and VoR sublines. Cells were treated with vorinostat for 2 days. (d) The MTT assay evaluating the effect of romidepsin (Romi) on the viability of H1944 and H1944R cells. Cells were treated with indicated concentrations of romidepsin for 3 days ( n = 3). (e) The expression levels of total and phosphorylated IGF-1R in the indicated NSCLC cells were determined by Western blot analysis. Cells were treated with vorinostat for 2 days. (f) Anchorage-independent colony formation assay evaluating vorinostat resistance of the indicated cells with combined treatment with vorinostat (1 μM) and an IGF-1R mAb (1 μg/ml) ( n = 3). **: P < 0.01; ***: P < 0.001, analyzed by two-sided Student’s t -test. Vo: vorinostat; Con: control.

Journal: Oncogene

Article Title: Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors

doi: 10.1038/onc.2016.92

Figure Lengend Snippet: (a and b) The effects of vorinostat on the viability (a) and anchorage-independent colony formation (b) of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. (a) Cell viability was determined by the MTT assay ( n = 3). (b) The soft agar colony formation assay was performed to evaluate the effect of 1 μM vorinostat on anchorage-independent colony formation. Data indicates the percentage of colony formation in vorinostat-treated cells compared with vehicle-treated control cells ( n = 3). (c) Immunoblots comparing the expression of cleaved caspase-3 (cl-Cas-3) between the indicated parental and VoR sublines. Cells were treated with vorinostat for 2 days. (d) The MTT assay evaluating the effect of romidepsin (Romi) on the viability of H1944 and H1944R cells. Cells were treated with indicated concentrations of romidepsin for 3 days ( n = 3). (e) The expression levels of total and phosphorylated IGF-1R in the indicated NSCLC cells were determined by Western blot analysis. Cells were treated with vorinostat for 2 days. (f) Anchorage-independent colony formation assay evaluating vorinostat resistance of the indicated cells with combined treatment with vorinostat (1 μM) and an IGF-1R mAb (1 μg/ml) ( n = 3). **: P < 0.01; ***: P < 0.001, analyzed by two-sided Student’s t -test. Vo: vorinostat; Con: control.

Article Snippet: Primary antibodies against IGF-1R (catalog # sc-713), actin (catalog # sc-1615), ubiquitin (catalog # sc-8017), GFP (catalog # sc-5385), and horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: MTT Assay, Soft Agar Assay, Control, Western Blot, Expressing, Colony Assay

(a and b) Real-time PCR assays analyzing the relative amounts of IGF1 and IGF2 transcription in the indicated parental (P) and their corresponding VoR sublines (a) and in various NSCLC cell lines with primary vorinostat resistance (b) by treatment with vorinostat (5 μM) for 2 days. Data indicates the fold increases of mRNA levels in vorinostat-treated cells compared with vehicle-treated control cells ( n = 3). (c) Determination of vorinostat-induced IGF2 production by ELISA ( n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. (d) Decreases in IGF2 levels in the CMs after silencing IGF2 expression using siRNAs, determined by ELISA ( n = 3). Cells were transfected with scrambled or IGF2 siRNAs for 6 h. The CMs were collected 48 h after transfection. (e) Immunoblots of total and phosphorylated IGF-1R expression in the indicated NSCLC cells with siRNA-mediated silencing of IGF2 expression and vorinostat (5 μM) treatment for 2 days. Cells were transfected with IGF2 siRNAs, and then treated with vorinostat. (e) The MTT assay evaluating the effects of vorinostat on the viability of indicated NSCLC cell lines with siRNA-mediated silencing of IGF2 expression ( n = 3). IGF2 siRNA-transfected cells were reseeded into 96 well plates and then treated with vorinostat (5 μM) for 3 days. *: P < 0.05; **: P < 0.01; ***: P < 0.001, analyzed by two-sided Student’s t -test. Vo: vorinostat.

Journal: Oncogene

Article Title: Essential role of insulin-like growth factor 2 in resistance to histone deacetylase inhibitors

doi: 10.1038/onc.2016.92

Figure Lengend Snippet: (a and b) Real-time PCR assays analyzing the relative amounts of IGF1 and IGF2 transcription in the indicated parental (P) and their corresponding VoR sublines (a) and in various NSCLC cell lines with primary vorinostat resistance (b) by treatment with vorinostat (5 μM) for 2 days. Data indicates the fold increases of mRNA levels in vorinostat-treated cells compared with vehicle-treated control cells ( n = 3). (c) Determination of vorinostat-induced IGF2 production by ELISA ( n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. (d) Decreases in IGF2 levels in the CMs after silencing IGF2 expression using siRNAs, determined by ELISA ( n = 3). Cells were transfected with scrambled or IGF2 siRNAs for 6 h. The CMs were collected 48 h after transfection. (e) Immunoblots of total and phosphorylated IGF-1R expression in the indicated NSCLC cells with siRNA-mediated silencing of IGF2 expression and vorinostat (5 μM) treatment for 2 days. Cells were transfected with IGF2 siRNAs, and then treated with vorinostat. (e) The MTT assay evaluating the effects of vorinostat on the viability of indicated NSCLC cell lines with siRNA-mediated silencing of IGF2 expression ( n = 3). IGF2 siRNA-transfected cells were reseeded into 96 well plates and then treated with vorinostat (5 μM) for 3 days. *: P < 0.05; **: P < 0.01; ***: P < 0.001, analyzed by two-sided Student’s t -test. Vo: vorinostat.

Article Snippet: Primary antibodies against IGF-1R (catalog # sc-713), actin (catalog # sc-1615), ubiquitin (catalog # sc-8017), GFP (catalog # sc-5385), and horseradish peroxidase (HRP)-conjugated secondary antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Techniques: Real-time Polymerase Chain Reaction, Control, Enzyme-linked Immunosorbent Assay, Expressing, Transfection, Western Blot, MTT Assay

(A) All three members of human TIM family interact with NUR77 as shown by coimmunoprecipitation assay. N=3 independent experiments (B) Top panel: Domain architecture of TIM-1. Middle Panel: Coimmunoprecipitation experiment demonstrating that only the entire extracellular domain (EED) and IgV domain (IgVD) of TIM-1 interact with NUR77 and not the mucin (MD) or the cytoplasmic domain (CD). Bottom panel: long exposure of the input blot showing the CD protein band. N=2 independent experiments. (C) The transactivation function of NUR77 is repressed by all three human TIM proteins in a dose dependent manner (Top panel). Full length TIM-1 protein is required for repression of NUR77 transcriptional activity (Bottom panel). Data from at least three independent experiments is presented. (D) Binding of NUR77 to its response elements (NBRE) is abrogated by the full length TIM proteins in an electrophoretic mobility shift assay using p32 labeled NBRE oligo. Competition with unlabelled probe (cold competition) reveals the specificity of NUR77 binding. A representative autoradiograph is shown (left) and the relative amount of NUR77 protein binding to NBRE probe was quantified from three independent experiments (right). ***, P<0.001, **, P<0.01, *,P<0.05.

Journal: Science signaling

Article Title: TIM Family Proteins Promote the Lysosomal Degradation of the Nuclear Receptor NUR77 *

doi: 10.1126/scisignal.2003200

Figure Lengend Snippet: (A) All three members of human TIM family interact with NUR77 as shown by coimmunoprecipitation assay. N=3 independent experiments (B) Top panel: Domain architecture of TIM-1. Middle Panel: Coimmunoprecipitation experiment demonstrating that only the entire extracellular domain (EED) and IgV domain (IgVD) of TIM-1 interact with NUR77 and not the mucin (MD) or the cytoplasmic domain (CD). Bottom panel: long exposure of the input blot showing the CD protein band. N=2 independent experiments. (C) The transactivation function of NUR77 is repressed by all three human TIM proteins in a dose dependent manner (Top panel). Full length TIM-1 protein is required for repression of NUR77 transcriptional activity (Bottom panel). Data from at least three independent experiments is presented. (D) Binding of NUR77 to its response elements (NBRE) is abrogated by the full length TIM proteins in an electrophoretic mobility shift assay using p32 labeled NBRE oligo. Competition with unlabelled probe (cold competition) reveals the specificity of NUR77 binding. A representative autoradiograph is shown (left) and the relative amount of NUR77 protein binding to NBRE probe was quantified from three independent experiments (right). ***, P<0.001, **, P<0.01, *,P<0.05.

Article Snippet: Western blotting and quantification of proteins Protein concentrations were quantified using Bio-rad DC kit and equal amounts of protein samples were separated on either 8% or 4–12% polyacrylamide gel and blotted onto PVDF membrane and probed with different antibodies as indicated (Anti-human NUR77 (Pharmingen), Anti-mouse NUR77 (BD), Anti-human TIM-1 (R&D), Anti-HA (Upstate/Millipore corp), Anti-β actin (Abcam), Anti-GFP (Abcam).

Techniques: Co-Immunoprecipitation Assay, Activity Assay, Binding Assay, Electrophoretic Mobility Shift Assay, Labeling, Autoradiography, Protein Binding

(A) Quantitative RT-PCR measurement of NUR77 transcript induced by PMA and ionomycin treatment in control and TIM-1 shRNA stable knockdown clones of 769-P cells (N=3 experiments). (B) Western analysis of the protein samples from (A) indicating the decrease in NUR77 abundance in the presence of TIM-1. Con, control. N= 3 independent experiments. (C) Overexpression of TIM-1 in HK-2 cells resulted in decreased NUR77 protein abundance induced by desferrioxamine (Des) (compare lanes: 3 and 4), which is perturbed by chloroquine treatment (CQ) (Lanes: 7 and 8). N=3 independent experiments. (D) Silencing of TIM-1 expression in HK-2 cells resulted in increased cell death in an in vitro epithelial cell injury model induced by a combination of ATP and glucose depletion and calcium overload. N= 3 independent experiments. IRI, Ischemia reperfusion injury (E) Confocal microscopy analysis of the localization pattern of endogenous hTIM-1 (green) in 769-P cells (Top panel) and GFP-tagged hTIM-1 stably expressed in Jurkat cells (Bottom panel). Scale bar, 10 µm. N=2 experiments. (F) Colocalization of ectopically expressed TIM-1 (green) in Cos-7 cells with markers of early endosomes (EEA1), Golgi complex (Giantin), and lysosomes (Lamp2a). Scale bar, 5 µm. Colocalization coefficients: hTIM-1/EEA1:0.34±0.06; hTIM-1/Giantin: 0.74±0.04; hTIM-1/Lamp2a: 0.55±0.08; n=5 cells each from two independent experiments (G). Colocalization of TIM-1 (blue) and ectopically expressed NUR77 (green) with lysosomes (Lysotracker red) in 769-P cells. Colocalization coefficients: hTim-1/NUR77: 0.59±0.12; hTIM-1/Lysotracker: 0.47±0.09; NUR77/Lysotracker: 0.51±0.08; and HK-2 cells; Colocalization coefficients: hTim-1/NUR77: 0.52+−.06; hTIM-1/Lysotracker: 0.56+0.08; NUR77/Lysotracker: 0.62+0.07; n=5 cells each from two independent experiments. Scale bar, 10 µm.

Journal: Science signaling

Article Title: TIM Family Proteins Promote the Lysosomal Degradation of the Nuclear Receptor NUR77 *

doi: 10.1126/scisignal.2003200

Figure Lengend Snippet: (A) Quantitative RT-PCR measurement of NUR77 transcript induced by PMA and ionomycin treatment in control and TIM-1 shRNA stable knockdown clones of 769-P cells (N=3 experiments). (B) Western analysis of the protein samples from (A) indicating the decrease in NUR77 abundance in the presence of TIM-1. Con, control. N= 3 independent experiments. (C) Overexpression of TIM-1 in HK-2 cells resulted in decreased NUR77 protein abundance induced by desferrioxamine (Des) (compare lanes: 3 and 4), which is perturbed by chloroquine treatment (CQ) (Lanes: 7 and 8). N=3 independent experiments. (D) Silencing of TIM-1 expression in HK-2 cells resulted in increased cell death in an in vitro epithelial cell injury model induced by a combination of ATP and glucose depletion and calcium overload. N= 3 independent experiments. IRI, Ischemia reperfusion injury (E) Confocal microscopy analysis of the localization pattern of endogenous hTIM-1 (green) in 769-P cells (Top panel) and GFP-tagged hTIM-1 stably expressed in Jurkat cells (Bottom panel). Scale bar, 10 µm. N=2 experiments. (F) Colocalization of ectopically expressed TIM-1 (green) in Cos-7 cells with markers of early endosomes (EEA1), Golgi complex (Giantin), and lysosomes (Lamp2a). Scale bar, 5 µm. Colocalization coefficients: hTIM-1/EEA1:0.34±0.06; hTIM-1/Giantin: 0.74±0.04; hTIM-1/Lamp2a: 0.55±0.08; n=5 cells each from two independent experiments (G). Colocalization of TIM-1 (blue) and ectopically expressed NUR77 (green) with lysosomes (Lysotracker red) in 769-P cells. Colocalization coefficients: hTim-1/NUR77: 0.59±0.12; hTIM-1/Lysotracker: 0.47±0.09; NUR77/Lysotracker: 0.51±0.08; and HK-2 cells; Colocalization coefficients: hTim-1/NUR77: 0.52+−.06; hTIM-1/Lysotracker: 0.56+0.08; NUR77/Lysotracker: 0.62+0.07; n=5 cells each from two independent experiments. Scale bar, 10 µm.

Article Snippet: Western blotting and quantification of proteins Protein concentrations were quantified using Bio-rad DC kit and equal amounts of protein samples were separated on either 8% or 4–12% polyacrylamide gel and blotted onto PVDF membrane and probed with different antibodies as indicated (Anti-human NUR77 (Pharmingen), Anti-mouse NUR77 (BD), Anti-human TIM-1 (R&D), Anti-HA (Upstate/Millipore corp), Anti-β actin (Abcam), Anti-GFP (Abcam).

Techniques: Quantitative RT-PCR, shRNA, Clone Assay, Western Blot, Over Expression, Expressing, In Vitro, Confocal Microscopy, Stable Transfection

(A) Left panel: Mutations in the MILIBS of TIM-1 abrogated TIM-1-mediated degradation of NUR77 protein (top). The double mutant of cytoplasmic tyrosine residues Y299 and Y335 partially restored the protein abundance of NUR77, but did not affect that of GFP (bottom). Right panel: Quantitation of NUR77 and GFP abundance in the presence of wild type and mutant TIM-1 based on three independent experiments. (B) Confocal microscopy analysis of the localization pattern of wild type, MILIBS, cytoplasmic tyrosine residue mutants of TIM-1, revealing increased cell surface localization of the MILIBS TIM-1 mutants. Scale bar, 5 µm (Left). Quantification of the localization of wild-type TIM-1 and the MILIBS mutant. N=10 cells each from three independent experiments (Right). (C) Inability of MILIBS mutants to mediate NUR77 degradation does not arise from lack of interaction with NUR77: Wild type and MILIBS mutant TIM-1 interact with NUR77 with equal efficiency demonstrated by GST pull down assay (Middle panel). IgV and mucin domains served as positive and negative controls of the interaction between TIM-1 and NUR77. Shown is a representative of three independent experiments.

Journal: Science signaling

Article Title: TIM Family Proteins Promote the Lysosomal Degradation of the Nuclear Receptor NUR77 *

doi: 10.1126/scisignal.2003200

Figure Lengend Snippet: (A) Left panel: Mutations in the MILIBS of TIM-1 abrogated TIM-1-mediated degradation of NUR77 protein (top). The double mutant of cytoplasmic tyrosine residues Y299 and Y335 partially restored the protein abundance of NUR77, but did not affect that of GFP (bottom). Right panel: Quantitation of NUR77 and GFP abundance in the presence of wild type and mutant TIM-1 based on three independent experiments. (B) Confocal microscopy analysis of the localization pattern of wild type, MILIBS, cytoplasmic tyrosine residue mutants of TIM-1, revealing increased cell surface localization of the MILIBS TIM-1 mutants. Scale bar, 5 µm (Left). Quantification of the localization of wild-type TIM-1 and the MILIBS mutant. N=10 cells each from three independent experiments (Right). (C) Inability of MILIBS mutants to mediate NUR77 degradation does not arise from lack of interaction with NUR77: Wild type and MILIBS mutant TIM-1 interact with NUR77 with equal efficiency demonstrated by GST pull down assay (Middle panel). IgV and mucin domains served as positive and negative controls of the interaction between TIM-1 and NUR77. Shown is a representative of three independent experiments.

Article Snippet: Western blotting and quantification of proteins Protein concentrations were quantified using Bio-rad DC kit and equal amounts of protein samples were separated on either 8% or 4–12% polyacrylamide gel and blotted onto PVDF membrane and probed with different antibodies as indicated (Anti-human NUR77 (Pharmingen), Anti-mouse NUR77 (BD), Anti-human TIM-1 (R&D), Anti-HA (Upstate/Millipore corp), Anti-β actin (Abcam), Anti-GFP (Abcam).

Techniques: Mutagenesis, Quantitation Assay, Confocal Microscopy, Pull Down Assay

(A) A form of TIM-1 lacking the signal peptide deleted TIM-1 is not glycosylated and unable to mediate degradation of NUR77. N= 2 independent experiments. (B) Perturbation of endocytic pathway using a dominant negative Dynamin construct (Dyn2K44A) did not affect TIM-1 mediated degradation of NUR77. N= 3 independent experiments (Left panel) and quantitation of protein abundance based on three independent experiments (Right panel). (C) Dominant negative constructs of Eps15 (DIII and D3delta2) substantially abrogated TIM-1 mediated degradation of NUR77. N=3 independent experiments (left panel). NUR77 protein abundance was quantified based on three independent experiments (right panel). (D) TIM-1 is constitutively endocytosed as revealed by the increased cell surface localization of transiently transfected TIM-1 in 293T cells, upon blockade of endocytosis using dominant negative constructs of dynamin-2 and Eps15 as assayed by flow cytometry. Perturbation of clathrin vesicle formation further enhanced the increased cell surface localization of the MILIBS mutant. Shaded histogram represents the control antibody staining and the open histogram represents hTIM-1 staining. Two peaks of TIM-1 staining reveal the dynamic cycling of TIM-1. N= 2 independent experiments.

Journal: Science signaling

Article Title: TIM Family Proteins Promote the Lysosomal Degradation of the Nuclear Receptor NUR77 *

doi: 10.1126/scisignal.2003200

Figure Lengend Snippet: (A) A form of TIM-1 lacking the signal peptide deleted TIM-1 is not glycosylated and unable to mediate degradation of NUR77. N= 2 independent experiments. (B) Perturbation of endocytic pathway using a dominant negative Dynamin construct (Dyn2K44A) did not affect TIM-1 mediated degradation of NUR77. N= 3 independent experiments (Left panel) and quantitation of protein abundance based on three independent experiments (Right panel). (C) Dominant negative constructs of Eps15 (DIII and D3delta2) substantially abrogated TIM-1 mediated degradation of NUR77. N=3 independent experiments (left panel). NUR77 protein abundance was quantified based on three independent experiments (right panel). (D) TIM-1 is constitutively endocytosed as revealed by the increased cell surface localization of transiently transfected TIM-1 in 293T cells, upon blockade of endocytosis using dominant negative constructs of dynamin-2 and Eps15 as assayed by flow cytometry. Perturbation of clathrin vesicle formation further enhanced the increased cell surface localization of the MILIBS mutant. Shaded histogram represents the control antibody staining and the open histogram represents hTIM-1 staining. Two peaks of TIM-1 staining reveal the dynamic cycling of TIM-1. N= 2 independent experiments.

Article Snippet: Western blotting and quantification of proteins Protein concentrations were quantified using Bio-rad DC kit and equal amounts of protein samples were separated on either 8% or 4–12% polyacrylamide gel and blotted onto PVDF membrane and probed with different antibodies as indicated (Anti-human NUR77 (Pharmingen), Anti-mouse NUR77 (BD), Anti-human TIM-1 (R&D), Anti-HA (Upstate/Millipore corp), Anti-β actin (Abcam), Anti-GFP (Abcam).

Techniques: Dominant Negative Mutation, Construct, Quantitation Assay, Transfection, Flow Cytometry, Mutagenesis, Staining

(A) Confocal immunofluorescence analysis of TIM-1 (green) colocalization with Clathrin (Top panel) and Caveolin-1 (Bottom panel) where yellow indicates colocalization. Scale bar, 10 µm. Colocalization coefficients: hTIM-1/Clathrin: 0.68±0.05; hTIM-1/Caveoli: 0.12±0.04; n=5 cells each from two independent experiments. (B). Retrograde translocation of TIM-1(green) from cell surface to lysosomes and endoplasmic reticulum through the trans-Golgi network in a clathrin-mediated pathway demonstrated by endocytosis assay; subcellular organelle markers are in red. Shown is a representative image. Scale bar, 10 µm. Colocalization coefficients: hTIM-1/EEA1: 0.57±0.05; hTIM-1/p230: 0.35±0.08; hTIM-1/Lamp2a (30 min): 0.46±0.09; hTIM-1/Clathrin: 0.38±0.06; hTIM-1/Lamp2a (60 min): 0.55±0.03; hTIM-1/Calnexin: 0.31±0.03; n=5 cells each from two independent experiments. (C to E) Model depicting the clathrin-mediated constitutive trafficking of TIM-1 and the phenomenon of TIM-1 mediated NUR77 degradation. TIM-1 and other TIM family members (red) are targeted to cell surface (C), prior to constitutive endocytosis through clathrin-coated vesicles (D). Following fusion with the trans-golgi network, TIM-1 undergoes retrograde translocation to endoplasmic reticulum (ER) and lysosomes (purple circles). TIM-1 might come in contact with NUR77 possibly in ER or vesicles leading to recruitment of this protein complex to PS-rich endosomes and lysosomes depending on the TIM-1-PS interaction, facilitating sorting of NUR77 to lysosomes and ultimately resulting in the degradation of NUR77 by lysosomal enzymes. TIM-1 is presumably retained in the vesicles (E).

Journal: Science signaling

Article Title: TIM Family Proteins Promote the Lysosomal Degradation of the Nuclear Receptor NUR77 *

doi: 10.1126/scisignal.2003200

Figure Lengend Snippet: (A) Confocal immunofluorescence analysis of TIM-1 (green) colocalization with Clathrin (Top panel) and Caveolin-1 (Bottom panel) where yellow indicates colocalization. Scale bar, 10 µm. Colocalization coefficients: hTIM-1/Clathrin: 0.68±0.05; hTIM-1/Caveoli: 0.12±0.04; n=5 cells each from two independent experiments. (B). Retrograde translocation of TIM-1(green) from cell surface to lysosomes and endoplasmic reticulum through the trans-Golgi network in a clathrin-mediated pathway demonstrated by endocytosis assay; subcellular organelle markers are in red. Shown is a representative image. Scale bar, 10 µm. Colocalization coefficients: hTIM-1/EEA1: 0.57±0.05; hTIM-1/p230: 0.35±0.08; hTIM-1/Lamp2a (30 min): 0.46±0.09; hTIM-1/Clathrin: 0.38±0.06; hTIM-1/Lamp2a (60 min): 0.55±0.03; hTIM-1/Calnexin: 0.31±0.03; n=5 cells each from two independent experiments. (C to E) Model depicting the clathrin-mediated constitutive trafficking of TIM-1 and the phenomenon of TIM-1 mediated NUR77 degradation. TIM-1 and other TIM family members (red) are targeted to cell surface (C), prior to constitutive endocytosis through clathrin-coated vesicles (D). Following fusion with the trans-golgi network, TIM-1 undergoes retrograde translocation to endoplasmic reticulum (ER) and lysosomes (purple circles). TIM-1 might come in contact with NUR77 possibly in ER or vesicles leading to recruitment of this protein complex to PS-rich endosomes and lysosomes depending on the TIM-1-PS interaction, facilitating sorting of NUR77 to lysosomes and ultimately resulting in the degradation of NUR77 by lysosomal enzymes. TIM-1 is presumably retained in the vesicles (E).

Article Snippet: Western blotting and quantification of proteins Protein concentrations were quantified using Bio-rad DC kit and equal amounts of protein samples were separated on either 8% or 4–12% polyacrylamide gel and blotted onto PVDF membrane and probed with different antibodies as indicated (Anti-human NUR77 (Pharmingen), Anti-mouse NUR77 (BD), Anti-human TIM-1 (R&D), Anti-HA (Upstate/Millipore corp), Anti-β actin (Abcam), Anti-GFP (Abcam).

Techniques: Immunofluorescence, Translocation Assay, Endocytosis Assay

P5 retinal whole-mount in situ hybridization of VEGF-A, VEGFR-1, and VEGFR-2 mRNA’s. (a) VEGF-A mRNA (pink) is detected anterior to the growing vessel front as outlined by (b) FITC-dextran perfusion of vessels (yellow green). Posterior to the vessel front, VEGF-A expression is suppressed (light yellow). (c) VEGFR-1 mRNA (pink) is detected in the central retina but is not seen at the anterior edge of vessels as outlined by (d) FITC-dextran perfusion of vessels (yellow). (e) VEGFR-2 mRNA (pink) is detected in the entire retina and does not correspond to the vessels (f) outlined in yellow.

Journal:

Article Title: Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity

doi: 10.1172/JCI200317808

Figure Lengend Snippet: P5 retinal whole-mount in situ hybridization of VEGF-A, VEGFR-1, and VEGFR-2 mRNA’s. (a) VEGF-A mRNA (pink) is detected anterior to the growing vessel front as outlined by (b) FITC-dextran perfusion of vessels (yellow green). Posterior to the vessel front, VEGF-A expression is suppressed (light yellow). (c) VEGFR-1 mRNA (pink) is detected in the central retina but is not seen at the anterior edge of vessels as outlined by (d) FITC-dextran perfusion of vessels (yellow). (e) VEGFR-2 mRNA (pink) is detected in the entire retina and does not correspond to the vessels (f) outlined in yellow.

Article Snippet: The sections were stained with primary antibodies against VEGFR-1 or VEGFR-2 (R&D Systems Inc.), and biotinylated Griffonia simplicifolia , thereafter G. simplicifolia , lectin I (endothelial cell specific) (Vector Laboratories Inc., Burlingame, California, USA) for 2 hours at room temperature.

Techniques: In Situ Hybridization, Expressing

Real-time RT-PCR quantification of VEGFR-1 and VEGFR-2 mRNA during retinal vascular development. Copy numbers of VEGFR-1 and VEGFR-2 mRNA/106 copies cyclophilin A control mRNA at specific timepoints were measured. (a) VEGFR-1 mRNA expression increases linearly with retinal vascular development; expression is 60-fold higher at P26 than at P3. (b) VEGFR-2 mRNA expression decreases modestly (<15%) during retinal vessel development. The ratio of VEGFR-2 mRNA to VEGFR-1 mRNA expression ranges from 200-fold at P3 to twofold at P26.

Journal:

Article Title: Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity

doi: 10.1172/JCI200317808

Figure Lengend Snippet: Real-time RT-PCR quantification of VEGFR-1 and VEGFR-2 mRNA during retinal vascular development. Copy numbers of VEGFR-1 and VEGFR-2 mRNA/106 copies cyclophilin A control mRNA at specific timepoints were measured. (a) VEGFR-1 mRNA expression increases linearly with retinal vascular development; expression is 60-fold higher at P26 than at P3. (b) VEGFR-2 mRNA expression decreases modestly (<15%) during retinal vessel development. The ratio of VEGFR-2 mRNA to VEGFR-1 mRNA expression ranges from 200-fold at P3 to twofold at P26.

Article Snippet: The sections were stained with primary antibodies against VEGFR-1 or VEGFR-2 (R&D Systems Inc.), and biotinylated Griffonia simplicifolia , thereafter G. simplicifolia , lectin I (endothelial cell specific) (Vector Laboratories Inc., Burlingame, California, USA) for 2 hours at room temperature.

Techniques: Quantitative RT-PCR, Expressing

Immunohistochemical localization of VEGFR-1 and VEGFR-2 protein in P2 and P5 retinal whole mounts. On P5, VEGFR-1 protein (red) is detected in a vascular pattern (a and c) and clearly coincides with endothelial cells (blue) as detected with G. simplicifolia I isolectin (d). (e) A merged image (purple) shows coincidence. (b and f) VEGFR-2–positive signal (red) is found in the neural retina, specifically in the interstices between vessels (blue) (g) in the merged image (h), which shows little or no overlap between vessels and VEGFR-2 staining. On P2, VEGFR-1 protein signal (green) (i) coincides with endothelial cells (red) (j) detected by lectin. In a merged image (k), retinal vessels coincide with the faint VEGFR-1 staining. The retinal vessel front is defined by an arrow. Some hyaloid vasculature (H) from incomplete removal on the vitreal surface of the P2 retina is also positive for VEGFR-1 signal. (l) VEGFR-2–positive signal (green) is found in the neural retina and does not coincide with endothelial capillaries (red) (m) in the merged image (n). Arrows indicate the vessel front.

Journal:

Article Title: Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity

doi: 10.1172/JCI200317808

Figure Lengend Snippet: Immunohistochemical localization of VEGFR-1 and VEGFR-2 protein in P2 and P5 retinal whole mounts. On P5, VEGFR-1 protein (red) is detected in a vascular pattern (a and c) and clearly coincides with endothelial cells (blue) as detected with G. simplicifolia I isolectin (d). (e) A merged image (purple) shows coincidence. (b and f) VEGFR-2–positive signal (red) is found in the neural retina, specifically in the interstices between vessels (blue) (g) in the merged image (h), which shows little or no overlap between vessels and VEGFR-2 staining. On P2, VEGFR-1 protein signal (green) (i) coincides with endothelial cells (red) (j) detected by lectin. In a merged image (k), retinal vessels coincide with the faint VEGFR-1 staining. The retinal vessel front is defined by an arrow. Some hyaloid vasculature (H) from incomplete removal on the vitreal surface of the P2 retina is also positive for VEGFR-1 signal. (l) VEGFR-2–positive signal (green) is found in the neural retina and does not coincide with endothelial capillaries (red) (m) in the merged image (n). Arrows indicate the vessel front.

Article Snippet: The sections were stained with primary antibodies against VEGFR-1 or VEGFR-2 (R&D Systems Inc.), and biotinylated Griffonia simplicifolia , thereafter G. simplicifolia , lectin I (endothelial cell specific) (Vector Laboratories Inc., Burlingame, California, USA) for 2 hours at room temperature.

Techniques: Immunohistochemical staining, Staining

Immunohistochemical localization of VEGFR-1 and VEGFR-2 protein in P5 and P15 retinal cross sections. (a–f) P5 immunohistochemical localization of (a) VEGFR-1, (d) VEGFR-2, (b and e) G. simplicifolia I isolectin–stained endothelial cells, and (c and f) merged images. (a) VEGFR-1 protein (green) is seen primarily in the ganglion cell layer (GCL) and is seen to overlap with (b) endothelial cells (red) when (c) the images are merged (yellow; indicated by arrows). (d) VEGFR-2–positive signal (green) is found in the GCL, the inner plexiform layer, the inner nuclear layer (INL), and the outer nuclear layer (ONL). (e) Vascular endothelial cells (red) do not overlap with VEGFR-2–positive cells in the merged image (f) and are not coincident with vessels (arrows). (g–l) P15 immunohistochemical localization of (g) VEGFR-1 and (j) VEGFR-2 staining and (h and k) isolectin-stained endothelial cells. (i and l) Merged images. VEGFR-1 protein (green in g) completely overlaps with endothelial cells (red in h) when the images are merged (yellow in i). Some VEGFR-2 signal (green in j) overlaps with endothelial cells (k) when the images are merged (yellow in l), whereas other VEGFR-2–positive cells (indicated by arrow in d and f) span the retina and are morphologically consistent with Muller cell structure. RPE/Ch, retinal pigment epithelium/choroid.

Journal:

Article Title: Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity

doi: 10.1172/JCI200317808

Figure Lengend Snippet: Immunohistochemical localization of VEGFR-1 and VEGFR-2 protein in P5 and P15 retinal cross sections. (a–f) P5 immunohistochemical localization of (a) VEGFR-1, (d) VEGFR-2, (b and e) G. simplicifolia I isolectin–stained endothelial cells, and (c and f) merged images. (a) VEGFR-1 protein (green) is seen primarily in the ganglion cell layer (GCL) and is seen to overlap with (b) endothelial cells (red) when (c) the images are merged (yellow; indicated by arrows). (d) VEGFR-2–positive signal (green) is found in the GCL, the inner plexiform layer, the inner nuclear layer (INL), and the outer nuclear layer (ONL). (e) Vascular endothelial cells (red) do not overlap with VEGFR-2–positive cells in the merged image (f) and are not coincident with vessels (arrows). (g–l) P15 immunohistochemical localization of (g) VEGFR-1 and (j) VEGFR-2 staining and (h and k) isolectin-stained endothelial cells. (i and l) Merged images. VEGFR-1 protein (green in g) completely overlaps with endothelial cells (red in h) when the images are merged (yellow in i). Some VEGFR-2 signal (green in j) overlaps with endothelial cells (k) when the images are merged (yellow in l), whereas other VEGFR-2–positive cells (indicated by arrow in d and f) span the retina and are morphologically consistent with Muller cell structure. RPE/Ch, retinal pigment epithelium/choroid.

Article Snippet: The sections were stained with primary antibodies against VEGFR-1 or VEGFR-2 (R&D Systems Inc.), and biotinylated Griffonia simplicifolia , thereafter G. simplicifolia , lectin I (endothelial cell specific) (Vector Laboratories Inc., Burlingame, California, USA) for 2 hours at room temperature.

Techniques: Immunohistochemical staining, Staining

PlGF-1, but not VEGF-E, prevents hyperoxia-induced retinal vessel loss, thus implicating VEGFR-1 in survival. PlGF-1: P8 FITC-dextran–perfused retinal flat-mount retina from a representative control mouse treated with room air (normoxia) (a) or a mouse given hyperoxic treatment (75% O2 for 17 hours at P7–P8) after intravitreal injection on P7 of (b) control BSS in one eye and (c) the VEGFR-1–specific ligand PlGF-1 in the contralateral eye. Vessels delineated with FITC show that PlGF-1 confers significant protection from oxygen-induced vessel loss compared with BBS control. (d) Analysis of nonvascularized area shows a greater than fourfold difference between eyes treated with PlGF-1 (22.2% ± 3.4% vascularized area) and eyes treated with BSS (5.1% ± 1.2%) (n = 6, P < 0.001). VEGF-E: FITC-dextran–perfused retinal flat mount of P8 control retina from representative room air–treated mouse (e) or oxygen-exposed mouse after intravitreal injections at P7 of (f) control BSS in one eye and (g) VEGFR-2–specific ligand VEGF-E in the contralateral eye. (h) Analysis of nonvascularized area shows no significant difference between VEGF-E– and BSS-treated eyes (n = 6, P = 0.87). Results are representative of two independent experiments.

Journal:

Article Title: Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity

doi: 10.1172/JCI200317808

Figure Lengend Snippet: PlGF-1, but not VEGF-E, prevents hyperoxia-induced retinal vessel loss, thus implicating VEGFR-1 in survival. PlGF-1: P8 FITC-dextran–perfused retinal flat-mount retina from a representative control mouse treated with room air (normoxia) (a) or a mouse given hyperoxic treatment (75% O2 for 17 hours at P7–P8) after intravitreal injection on P7 of (b) control BSS in one eye and (c) the VEGFR-1–specific ligand PlGF-1 in the contralateral eye. Vessels delineated with FITC show that PlGF-1 confers significant protection from oxygen-induced vessel loss compared with BBS control. (d) Analysis of nonvascularized area shows a greater than fourfold difference between eyes treated with PlGF-1 (22.2% ± 3.4% vascularized area) and eyes treated with BSS (5.1% ± 1.2%) (n = 6, P < 0.001). VEGF-E: FITC-dextran–perfused retinal flat mount of P8 control retina from representative room air–treated mouse (e) or oxygen-exposed mouse after intravitreal injections at P7 of (f) control BSS in one eye and (g) VEGFR-2–specific ligand VEGF-E in the contralateral eye. (h) Analysis of nonvascularized area shows no significant difference between VEGF-E– and BSS-treated eyes (n = 6, P = 0.87). Results are representative of two independent experiments.

Article Snippet: The sections were stained with primary antibodies against VEGFR-1 or VEGFR-2 (R&D Systems Inc.), and biotinylated Griffonia simplicifolia , thereafter G. simplicifolia , lectin I (endothelial cell specific) (Vector Laboratories Inc., Burlingame, California, USA) for 2 hours at room temperature.

Techniques: Injection

Activation of VEGFR-1 by PlGF-1 does not increase normal retinal vessel growth or revascularization. (a) Intravitreal injections at P3 of control (BSS) in one eye and PlGF-1 in the contralateral eye (n = 6). Retinal vessel growth area was measured in whole mounts at P5. PlGF-1–injected eyes had a mean of 41.67% ± 5.63% of the retina vascularized. Similarly, 42.18% ± 8.60% of the BSS-injected contralateral control eyes were vascularized (P = 0.91). Results are representative of two independent experiments. (b) Vessel revascularization was measured in P15 mice after induction of vessel loss by oxygen (P7–P12) followed by intravitreal injections of BSS at P13 in one eye and PlGF-1 in the contralateral eye. PlGF-1–injected eyes were 26.32% ± 2.62% vascularized; similarly, BSS-treated contralateral control eyes were 26.29% ± 2.86% vascularized (n = 6, P = 0.99). Results are representative of two independent experiments. (c) In eyes with oxygen-induced retinopathy, the mean number of vascular nuclei extending into the vitreous at P17 in ten retinal cross sections per eye (n = 8 eyes) was counted after intravitreal injections of BSS at P13 (after 5 days of 75% O2 treatment, from P7 to P12) in one eye and PlGF-1 in the contralateral eye. BSS- and PlGF-1–injected eyes showed means of 9.98 and 9.96 vascular nuclei (P = 0.61), respectively, indicating no stimulation of proliferation by PlGF-1.

Journal:

Article Title: Selective stimulation of VEGFR-1 prevents oxygen-induced retinal vascular degeneration in retinopathy of prematurity

doi: 10.1172/JCI200317808

Figure Lengend Snippet: Activation of VEGFR-1 by PlGF-1 does not increase normal retinal vessel growth or revascularization. (a) Intravitreal injections at P3 of control (BSS) in one eye and PlGF-1 in the contralateral eye (n = 6). Retinal vessel growth area was measured in whole mounts at P5. PlGF-1–injected eyes had a mean of 41.67% ± 5.63% of the retina vascularized. Similarly, 42.18% ± 8.60% of the BSS-injected contralateral control eyes were vascularized (P = 0.91). Results are representative of two independent experiments. (b) Vessel revascularization was measured in P15 mice after induction of vessel loss by oxygen (P7–P12) followed by intravitreal injections of BSS at P13 in one eye and PlGF-1 in the contralateral eye. PlGF-1–injected eyes were 26.32% ± 2.62% vascularized; similarly, BSS-treated contralateral control eyes were 26.29% ± 2.86% vascularized (n = 6, P = 0.99). Results are representative of two independent experiments. (c) In eyes with oxygen-induced retinopathy, the mean number of vascular nuclei extending into the vitreous at P17 in ten retinal cross sections per eye (n = 8 eyes) was counted after intravitreal injections of BSS at P13 (after 5 days of 75% O2 treatment, from P7 to P12) in one eye and PlGF-1 in the contralateral eye. BSS- and PlGF-1–injected eyes showed means of 9.98 and 9.96 vascular nuclei (P = 0.61), respectively, indicating no stimulation of proliferation by PlGF-1.

Article Snippet: The sections were stained with primary antibodies against VEGFR-1 or VEGFR-2 (R&D Systems Inc.), and biotinylated Griffonia simplicifolia , thereafter G. simplicifolia , lectin I (endothelial cell specific) (Vector Laboratories Inc., Burlingame, California, USA) for 2 hours at room temperature.

Techniques: Activation Assay, Injection